Sigurd Elz

2.2k total citations
87 papers, 1.9k citations indexed

About

Sigurd Elz is a scholar working on Molecular Biology, Immunology and Organic Chemistry. According to data from OpenAlex, Sigurd Elz has authored 87 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 67 papers in Molecular Biology, 45 papers in Immunology and 27 papers in Organic Chemistry. Recurrent topics in Sigurd Elz's work include Mast cells and histamine (45 papers), Receptor Mechanisms and Signaling (39 papers) and Chemical Synthesis and Analysis (30 papers). Sigurd Elz is often cited by papers focused on Mast cells and histamine (45 papers), Receptor Mechanisms and Signaling (39 papers) and Chemical Synthesis and Analysis (30 papers). Sigurd Elz collaborates with scholars based in Germany, France and Poland. Sigurd Elz's co-authors include Walter Schunack, Heinz H. Pertz, Armin Buschauer, Roland Seifert, Stefan Dove, Holger Stark, Xavier Ligneau, C. Robin Ganellin, Andreas Sellmer and Siavosh Mahboobi and has published in prestigious journals such as Journal of Medicinal Chemistry, Journal of Pharmacology and Experimental Therapeutics and Molecules.

In The Last Decade

Sigurd Elz

84 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sigurd Elz Germany 25 1.3k 870 403 350 215 87 1.9k
Wenying Chai United States 18 616 0.5× 515 0.6× 460 1.1× 125 0.4× 81 0.4× 22 1.2k
Andrea Straßer Germany 21 906 0.7× 524 0.6× 146 0.4× 369 1.1× 60 0.3× 59 1.3k
M. ROBBA France 16 970 0.8× 686 0.8× 1.2k 3.0× 163 0.5× 335 1.6× 213 2.3k
Obbe P. Zuiderveld Netherlands 19 600 0.5× 426 0.5× 450 1.1× 104 0.3× 74 0.3× 33 1.1k
Curt A. Dvorak United States 19 536 0.4× 338 0.4× 413 1.0× 182 0.5× 74 0.3× 37 1.3k
Ramin Faghih United States 22 873 0.7× 667 0.8× 230 0.6× 140 0.4× 290 1.3× 43 1.3k
Chae Hee Kang United States 19 1.0k 0.8× 317 0.4× 62 0.2× 325 0.9× 133 0.6× 28 1.3k
Lisa D. Aimone United States 19 654 0.5× 180 0.2× 435 1.1× 211 0.6× 46 0.2× 59 1.2k
Andrew O. Stewart United States 27 826 0.6× 71 0.1× 757 1.9× 290 0.8× 92 0.4× 53 1.8k
Kilian W. Conde‐Frieboes Denmark 18 960 0.8× 103 0.1× 258 0.6× 140 0.4× 22 0.1× 33 1.4k

Countries citing papers authored by Sigurd Elz

Since Specialization
Citations

This map shows the geographic impact of Sigurd Elz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sigurd Elz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sigurd Elz more than expected).

Fields of papers citing papers by Sigurd Elz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sigurd Elz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sigurd Elz. The network helps show where Sigurd Elz may publish in the future.

Co-authorship network of co-authors of Sigurd Elz

This figure shows the co-authorship network connecting the top 25 collaborators of Sigurd Elz. A scholar is included among the top collaborators of Sigurd Elz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sigurd Elz. Sigurd Elz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sellmer, Andreas, Karsten Spiekermann, Maria Reinecke, et al.. (2025). Novel water-soluble and highly efficient dual type I/II next generation inhibitors of FMS-like tyrosine kinase 3 (FLT3). European Journal of Medicinal Chemistry. 296. 117849–117849. 2 indexed citations
2.
Pockes, Steffen, Sabina Podlewska, Gniewomir Latacz, et al.. (2020). Structural modifications in the distal, regulatory region of histamine H3 receptor antagonists leading to the identification of a potent anti-obesity agent. European Journal of Medicinal Chemistry. 213. 113041–113041. 13 indexed citations
3.
Sellmer, Andreas, Oliver H. Krämer, Stefan Dove, et al.. (2018). Design and biological evaluation of tetrahydro-β-carboline derivatives as highly potent histone deacetylase 6 (HDAC6) inhibitors. European Journal of Medicinal Chemistry. 152. 329–357. 36 indexed citations
4.
Lieb, Spencer, Timo Littmann, Miho Tanaka, et al.. (2016). Label-free versus conventional cellular assays: Functional investigations on the human histamine H1 receptor. Pharmacological Research. 114. 13–26. 21 indexed citations
5.
Wittmann, Hans‐Joachim, Michael Bodensteiner, Günther Bernhardt, et al.. (2016). Dibenzo[ b , f ][1,4]oxazepines and dibenzo[ b , e ]oxepines: Influence of the chlorine substitution pattern on the pharmacology at the H 1 R, H 4 R, 5-HT 2A R and other selected GPCRs. Pharmacological Research. 113(Pt A). 610–625. 9 indexed citations
6.
Elz, Sigurd, et al.. (2014). [3H]UR‐DE257: Development of a Tritium‐Labeled Squaramide‐Type Selective Histamine H2 Receptor Antagonist. ChemMedChem. 10(1). 83–93. 26 indexed citations
7.
Wittmann, Hans‐Joachim, et al.. (2011). Mepyramine–JNJ7777120-hybrid compounds show high affinity to hH1R, but low affinity to hH4R. Bioorganic & Medicinal Chemistry Letters. 21(21). 6274–6280. 9 indexed citations
8.
Straßer, Andrea, et al.. (2008). Molecular Basis for the Selective Interaction of Synthetic Agonists with the Human Histamine H1-Receptor Compared with the Guinea Pig H1-Receptor. Molecular Pharmacology. 75(3). 454–465. 24 indexed citations
9.
Ghorai, Prasanta, David Schnell, Sigurd Elz, et al.. (2008). NG‐Acylated Aminothiazolylpropylguanidines as Potent and Selective Histamine H2 Receptor Agonists. ChemMedChem. 4(2). 232–240. 35 indexed citations
10.
Mahboobi, Siavosh, Andrea Uecker, Andreas Sellmer, et al.. (2006). Inhibition of FLT3 and PDGFR tyrosine kinase activity by bis(benzo[b]furan-2-yl)methanones. Bioorganic & Medicinal Chemistry. 15(5). 2187–2197. 25 indexed citations
11.
Mahboobi, Siavosh, et al.. (2006). 3-Bromo-4-(1H-3-indolyl)-2,5-dihydro-1H-2,5-pyrroledione derivatives as new lead compounds for antibacterially active substances. European Journal of Medicinal Chemistry. 41(2). 176–191. 43 indexed citations
12.
Patil, Rameshwar, Sigurd Elz, & Oliver Reiser. (2005). Side-chain modified analogues of histaprodifen: Asymmetric synthesis and histamine H1-receptor activity. Bioorganic & Medicinal Chemistry Letters. 16(3). 672–676. 3 indexed citations
13.
Pertz, Heinz H., Sigurd Elz, & Walter Schunack. (2004). Structure-Activity Relationships of Histamine H1-Receptor Agonists. Mini-Reviews in Medicinal Chemistry. 4(9). 935–940. 13 indexed citations
14.
Łażewska, Dorota, et al.. (2001). Piperidine-containing histamine H3-receptor antagonists of the carbamate series: variation of the spacer length.. PubMed. 56(12). 927–32. 3 indexed citations
15.
16.
Malinowska, Barbara, Jarosław Piszcz, Eberhard Schlicker, et al.. (1999). Histaprodifen, methylhistaprodifen, and dimethylhistaprodifen are potent H1-receptor agonists in the pithed and in the anaesthetized rat. Naunyn-Schmiedeberg s Archives of Pharmacology. 359(1). 11–16. 13 indexed citations
17.
Timm, Jörg, et al.. (1998). H2 receptor-mediated facilitation and H3 receptor-mediated inhibition of noradrenaline release in the guinea-pig brain. Naunyn-Schmiedeberg s Archives of Pharmacology. 357(3). 232–239. 23 indexed citations
18.
19.
20.
Elz, Sigurd, et al.. (1988). Halogenderivate von N-[3-(Imidazol-4-yl)propyl]-N'-(2-phenylthioalkyl)guanidinen. University of Regensburg Publication Server (University of Regensburg). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Wenying Chai Breakdown of academic impact, for papers by Andrea Straßer Breakdown of academic impact, for papers by M. ROBBA Breakdown of academic impact, for papers by Obbe P. Zuiderveld Breakdown of academic impact, for papers by Curt A. Dvorak Breakdown of academic impact, for papers by Ramin Faghih Breakdown of academic impact, for papers by Chae Hee Kang Breakdown of academic impact, for papers by Lisa D. Aimone Breakdown of academic impact, for papers by Andrew O. Stewart Breakdown of academic impact, for papers by Kilian W. Conde‐Frieboes
Rankless by CCL
2026